Nextracker (NASDAQ: NXT), a leading solar technology platform provider, and T1 Energy Inc. (NYSE: TE), an advanced ...

MSI, a world-renowned leader in high-performance gaming hardware, is proud to serve as the exclusive gaming PC and laptop partner for Red Bull League of Its Own. With over 50 cutting-edge systems ...

Billions are being invested to revolutionize these American airports. Uncover the groundbreaking developments set to ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...

NSW taxi drivers who overcharge customers could be hit with a $3000 penalty in a fresh bid to crack down on fare-related ...

Q3 2025 Earnings Call October 15, 2025 3:00 AM EDTCompany ParticipantsBenat Ortega - CEO & DirectorNicolas Dutreuil - Deputy ...

Pembrolizumab (Keytruda) administered before and after surgery reduced the risk of death by 26% vs placebo in patients with early-stage non–small cell lung cancer (NSCLC), according to 5-year ...

Fluorescent nanodiamonds release a small molecule inside breast cancer cells and use quantum sensing to watch how the drug ...

The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder ...

Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...